4D Molecular Therapeutics Inc

FDMT remains in a Stage 2 – Advancing regime with an active Momentum Breakout and Lockout Rally signaling strong institutional demand. Despite extreme overbought readings and price extended above the EMAs, Lockout Rally dynamics support immediate participation in the medium-term uptrend. Rising EMAs and expanding volume confirm trend integrity, making a Buy Now posture appropriate, while recognizing risk of corrective pullbacks from these overextended levels.

• ↑Completed enrollment in 4FRONT-2 Phase 3 trial for 4D-150 in Wet AMD, enabling potential FDA submission.
• ↑Secured $200 m credit facility from Hercules Capital to fund trials through 2027.
• ↓Earnings yield of –3.56% suggests the stock is overvalued relative to earnings.